We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

In addition to our progress across the U.S., we've also made ... a leading European specialty pharmaceutical company. Under this license and supply agreement, Norgine will commercialize ...

March 28 (Reuters) - U.S. shipping and logistics company IMC Pro International has ... These chemicals were slated to be routed across the border into Mexico, authorities said.

Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded RMB222.0 ...

India’s benchmark equity indices, Sensex and Nifty, traded lower on Wednesday as investors awaited clarity on upcoming U.S.

The company's earnings totaled -$39.82 million, or -$0.20 per share. This compares with -$19.13 million, or -$0.10 per share, last year. X4 Pharmaceuticals ... of subjects across several platforms.

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results ...

Also in January 2025, the company announced that it had entered into an exclusive licensing and supply agreement under which Norgine Pharma UK will ... counts (ANC) across all study populations ...